Skip to main content
. Author manuscript; available in PMC: 2016 Feb 8.
Published in final edited form as: J Control Release. 2015 Sep 25;219:215–223. doi: 10.1016/j.jconrel.2015.09.042

Figure 2.

Figure 2

Drug delivery systems for targeting organ-specific metastases. A. Nanoarchitectures provide sizes favorable for delivery as well as the presentation of multiple targeting ligands for increased avidity and the concentration of payload. B. In targeting a particular tissue, design considerations include the filtering characteristics of the organ and specialized physiological barriers that hinder uptake. C. These considerations lead to a restricted set of variables to be optimized experimentally, and D. implemented for successful targeting and imaging/eradication of metastases.